HomeIndiaJ&J's single-dose Covid vaccine gets approval for emergency use in India

J&J’s single-dose Covid vaccine gets approval for emergency use in India



Johnson and Johnson’s single-dose Covid vaccine has been given approval for emergency use in India, announced Union Health Minister Mansukh Mandaviya on Twitter on Saturday.


“Now India has 5 EUA vaccines. This will further boost our nation’s collective fight against #COVID19,” tweeted Mandaviya.


The US pharma major had sought approval for its single shot vaccine from the Indian regulator earlier this week.


In April the company had indicated that it was in discussions with the Indian government about starting a bridging clinical study for the vaccine.


India has now done away with the provision of trial for Covid-19 vaccines that are approved by foreign regulators like the USFDA or UK-MHRA, and thus the vaccine maker was asked to apply directly for approval.



The J&J spokesperson had earlier said the vaccine would come to India through its collaboration with Indian drug firm Biological E in Hyderabad, which will produce it.


“Biological E will be an important part of our global supply chain network, helping to supply our vaccine through the extensive collaborations and partnerships we have with governments, health authorities and organisations such as Gavi and the Covax Facility,” the spokesperson said.


Earlier, Mahima Datla, MD and CEO of Biological E, had told Business Standard that J&J was looking to produce 500-600 million doses at its plant but did not specify whether this is a per annum figure or the total doses specified in the contract.


While exact details have not been revealed, the J&J vaccine is likely to be made in India under the Quad Vaccine Partnership, an alliance between India, the US, Japan and Australia.


Biological E has not revealed its manufacturing or stock-piling plans, nor whether production will be scaled up from the initial quantity.


J&J has said earlier its vaccine can remain stable at 2-8 degree Celsius for up to three months and the company will ship the vaccine using the same cold chain technologies it uses today to transport treatments for cancer, immunological disorders and other medicines.


The vaccine Ad26.COV2.S developed by J&J’s arm Janssen got an emergency use authorisation from the US Food and Drug Regulator (USFDA) in February this year based on data from the phase 3 Ensemble study. J&J conducted clinical trials on 43,783 participants across countries including the US.


The USFDA noted that “the vaccine was approximately 77 per cent effective in preventing severe/critical COVID-19 occurring at least 14 days after vaccination and 85 per cent effective in preventing severe/critical COVID-19 occurring at least 28 days after vaccination.”


The European Medical Agency (EMA) authorised the vaccine in March.


The United States Centers for Disease Control and Prevention, the national public health agency of the US, has said that the vaccine had high efficacy at preventing hospitalisation and death in people who did get sick. The CDC has also noted that the Janssen vaccine was 66.3 per cent effective in clinical trials at preventing laboratory confirmed Covid-19 illness in people who had no evidence of prior infection 2 weeks after receiving the vaccine.


“Early evidence suggests that the J&J/Janssen vaccine might provide protection against asymptomatic infection, which is when a person is infected by the virus that causes COVID-19 but does not get sick,” the CDC has noted.

Dear Reader,

Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.

We, however, have a request.

As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.

Support quality journalism and subscribe to Business Standard.

Digital Editor



Source link

- Advertisment -